High-performance liquid chromatographic method for the determination of moclobemide and its two major metabolites in human plasma

Journal of Pharmaceutical and Biomedical Analysis

Volumn 43, Issue 4, 2007, Pages 1416-1422

  Rakic, Anita ^a   Miljkovic, Branislava ^b   Pokrajac, Milena ^b   Vucicevic, Katarina ^b  

^a Medicines and Medical Devices Agency of Serbia   (Serbia)

^b School of Pharmacy   (Serbia)

Author keywords

HPLC; Metabolites; Moclobemide; Plasma; Solid phase extraction

Indexed keywords

4 [2 (4 CHLOROBENZAMIDO)ETHYL]MORPHOLINE 4 OXIDE; 4 CHLORO N [2 (3 OXOMORPHOLINO)ETHYL]BENZAMIDE; ACETONITRILE; ACETYLSALICYLIC ACID; AMOXICILLIN; AMPICILLIN; ASCORBIC ACID; ATENOLOL; AUROMID; CAFFEINE; CAPTOPRIL; CARBAMAZEPINE; CEFACLOR; CEFALEXIN; CHLORPROMAZINE; CIPROFLOXACIN; CLONAZEPAM; DIAZEPAM; DICLOFENAC; DIPOTASSIUM HYDROGEN PHOSPHATE; DIPYRONE; ENALAPRIL; ERYTHROMYCIN; HYDROCHLOROTHIAZIDE; IBUPROFEN; INDAPAMIDE; METOPROLOL; MOCLOBEMIDE; NAPROXEN; TRIETHYLAMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACCURACY; ACIDITY; ANALYTICAL ERROR; ARTICLE; CALIBRATION; DEPRESSION; DEVICE; DRUG BLOOD LEVEL; DRUG DETERMINATION; FLOW RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; PLASMA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SOLID PHASE EXTRACTION; STEADY STATE; VALIDATION PROCESS;

BENZAMIDES; BLOOD; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; MOCLOBEMIDE; MOLECULAR STRUCTURE; MORPHOLINES; SENSITIVITY AND SPECIFICITY; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 33847237604     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2006.10.032     Document Type: Article

References (23)

1. Bonnet U. CNS Drug Rev. 9 (2003) 97-140
2. Jauch R., Griesser E., Oesterhelt G., Arnold W., Meister W., Ziegler W.H., and Guentert T.W. Acta Psychiatr. Scand. Suppl. 360 (1990) 87-90
3. Mayersohn M., and Guentert T.W. Clin. Pharmacokinet. 29 (1995) 292-332
4. Maguire K.P., Norman T.R., Davies B.M., and Burrows G.D. J. Chromatogr. 278 (1983) 429-433
5. Raaflaub J., Haefelfinger P., and Trautmann K.H. Arzneim.-Forsch. 34 (1984) 80-82
6. Gex-Fabry M., Balant-Gorgia A.E., and Balant L.P. Ther. Drug Monit. 17 (1995) 39-46
7. Gaillard Y., and Pepin G. Forensic Sci. Int. 87 (1997) 239-248
8. Geschke R., Korner J., and Eggers H. J. Chromatogr. 420 (1987) 111-120
9. Misztal G., Skibinski R., Olajossy M., and Paw B. J. Pharm. Biomed. Anal. 30 (2002) 1277-1285
10. Hoskins J.M., Gross A.S., Shenfield G.M., and Rivory L.P. J. Chromatogr. B 754 (2001) 319-326
11. Amini H., Shahmir B., and Ahmadiani A. J. Chromatogr. B 807 (2004) 271-275
12. Ibister G.K., Hackett L.P., Dawson A.H., Whyte I.M., and Smith A.J. Br. J. Clin. Pharmacol. 56 (2003) 441-450
13. Shoerlin M.P., Mayersohn M., Korn A., and Eggers H. Clin. Pharmacol. Ther. 42 (1987) 395-404
14. Yu K.S., et al. Clin. Pharmacol. Ther. 69 (2001) 266-273
15. Guentert T.W., Tucker G., Korn A., Pfefen J.P., Haefelfinger P., and Schoerlin M.P. Acta Psychiatr. Scand. Suppl. 360 (1990) 91-93
16. Dingemanse J., Wood N., Guentert T., Oie S., Ouwerkerk M., and Amrein R. Psychopharmacology 140 (1998) 164-172
17. Huck C.W., and Bonn G.K. J. Chromatogr. A 885 (2000) 51-72
18. Almeida A.M., Castel-Branco M.M., and Falcao A.C. J. Chromatogr. B 774 (2002) 215-222
19. FDA Guidance for Industry on Biomedical Method Validation, 2001. http://www.fda.gov.cder.guidance/index.htm.
20. Ritchel W.A., and Kearns G.L. Handbook of Basic Pharmacocinetics Including Clinical Applications (1999), American Pharmaceutical Association, Washington
21. AHFS Drug Information, American Society of Health-System Pharmacist Inc., 2006.
22. Fleming J., and Chetty M. Clin. Neuropharmacol. 28 (2005) 96-101
23. Thurman E.M., and Mills M.S. Solid-Phase Extraction: Principles and Practice (1998), John Wiley & Sons Inc., New York